karelroden
50+ Views

purpleheart

Preparations containing metal ions (antacids, preparations containing iron, magnesium, calcium) form inactive chelates with tetracycline, and therefore it is necessary to avoid their simultaneous administration.
It is necessary to avoid combinations with penicillins, cephalosporins that have a bactericidal effect and are antagonists of bacteriostatic antibiotics (including buy Tetracycline Capsules 500 mg with No Prescription Tetracyclines).
With the simultaneous use of tetracycline with retinol, intracranial hypertension may develop. With simultaneous use with colestiramine or colestipol, there is a violation of the absorption of tetracycline.

Tetracycline tablets are prescribed for etiotropic therapy of pathologies of infectious and inflammatory origin, the development of which is caused by the multiplication of pathogens sensitive to the main component of the drug. Typically, the drug is used in the treatment of: pneumonia - an infectious pneumonia; acne complicated by infectious inflammation; pleural empyema - accumulations of pus inside the pleural cavity; osteomyelitis - purulent lesions of bone tissue having different localization; bronchitis - infectious inflammation of the bronchi; a variety of intestinal infections; cholecystitis - lesions of the gallbladder; conjunctivitis - inflammation of the conjunctiva; pyelonephritis - purulent-inflammatory processes in the pyelocaliceal system of the kidneys; blepharitis - infectious and inflammatory processes on the eyelids; endometritis - inflammation of the uterine mucosa; brucellosis - a specific form of infection that is transmitted from certain animal species; endocarditis - an infectious process that occurs on the surface of the mucous membranes in the myocardial cavities; gonorrhea - a genital infection characterized by purulent lesions of the lower urinary tract; prostatitis - inflammation of the prostate in the stronger sex; syphilis - an infection that is transmitted through sexual contact.

Along with this, the drug is prescribed for the prevention of the development of infectious complications after surgery.
Side effects From the nervous system and sensory organs: increased intracranial pressure, dizziness or instability. From the cardiovascular system and blood (hematopoiesis, hemostasis): hemolytic anemia, thrombocytopenia, neutropenia. From the gastrointestinal tract: loss of appetite, nausea, vomiting, diarrhea, glossitis, esophagitis, gastritis, ulceration of the stomach and duodenum, hypertrophy of the papillae of the tongue, dysphagia, hepatotoxic effect, increased activity of hepatic transaminases, hyperbilirubinemia, pancreatic benignitis, anti-tuberculosis, antibiotics. From the genitourinary system: nephrotoxic effect, azotemia, hypercreatininemia. Allergic reactions: maculopapular rash, flushing of the skin, angioedema, anaphylactoid reactions, drug systemic lupus erythematosus.
Other: photosensitization, violation of the formation of bone and dental tissue, discoloration of tooth enamel in children, superinfection, candidiasis, hypovitaminosis B.
Comment
Suggested
Recent
Cards you may also be interested in
6 Easy Ways To A Smooth Neck
Because the skin on your neck is some of the thinnest on your body, it is also one of the first places to show signs of ageing. Here are six ways to make your neck look younger and address everything from sun damage to sagging on this delicate area. 1. WEAR SUNSCREEN EVERY SINGLE DAY. Your dermatologist will agree that a nickel-sized amount of sunscreen applied to your neck and chest every day will help prevent collagen breakdown and the formation of sunspots. Don't forget to massage the sides and back of your neck. 2. MAINTAIN YOUR SKIN'S MOISTURIZATION. Again, the skin on your neck is thinner and has fewer oil glands than the rest of your body, so keeping the area hydrated is essential for a smoother overall texture. Look for peptide-containing creams (which can help stimulate new collagen growth) and apply them in gentle, upward strokes from your chest to your jawline. 3. RECLAIM YOUR BEAUTY SLEEP. Do you always wake up with pillow lines on the side of your neck? Apply one of these silicone patches before going to bed to keep your skin from crinkling while you sleep. You'll wake up with a smoother neck and less chance of further damage. 4. FOCUS ON CORRECT POSTURE. The amount of time we spend looking down at our phones and screens has resulted in what we now refer to as "tech neck." The simplest solution would be to limit screen time entirely, but more realistically, you should keep everything as close to eye level as possible to avoid unnecessary wrinkling. 5. GIVE LASER TREATMENTS A GO AHEAD. Still have fine lines on your neck? Fraxel lasers, stimulate your body's natural repair process to promote collagen growth. Fraxel can also be used to treat any dark spots or broken capillaries in the area, giving you a more even complexion. 6. ULTRASOUND TREATMENT FOR SERIOUS REPAIR. Ultherapy or Ultracel is your best non-surgical option for deeper, more stubborn lines and sagging. The FDA-approved treatment uses heat generated by focused sonic waves to penetrate deeper into the skin and stimulate the production of new collagen. Take note that the effect is gradual, and most patients notice a lifting effect three to six months after the initial treatment, so be patient.
Significant COVID-19 Impact on Nivolumab in Healthcare Industry
COVID-19 Impact on Nivolumab in Healthcare Industry COVID-19 (Coronavirus) has affected the day-to-day life of people and has slowed down the economies worldwide. The pandemic has affected millions of people who either got sick or died due to the spread of this disease. Within a few months, coronavirus disease (COVID-19), which originated from China, became a pandemic, with more than 30 million people being infected till date. There are now numerous vaccines in use. The first mass vaccination program commenced in early December 2020, and as of 15 February 2021, 175.3 million vaccine doses have been administered. There is an added complexity because of COVID-19 diagnosis in cancer patients, particularly while on active treatment with immunotherapy like nivolumab. COVID-19 could cause more harm to cancer patients. In order to prevent the infection from spreading, the patient’s number and new diagnosis have been less during the COVID 19. The COVID-19 pandemic has led to a dramatic loss of human life worldwide and presents an unprecedented challenge to public health, food systems, and the world of work. Still, there is an increase in the demand for cancer treatment with immunotherapy drugs like nivolumab during the second quarter of 2020 with the rise in awareness regarding health and new product launches in countries. IMPACT ON PRICE COVID-19 is significantly decreasing commercial activity in every area of the business sector. The economy has been decreased during the pandemic with the restricted and disrupted supply and sales of products and devices. The cost of medication and treatment of nivolumab has been increased due to the increasing demand for this drug during COVID-19. This contributed to the increased expenses and prices of immunotherapy drugs. Changes in the economy and other factors have caused consequences, including the decrease in the sales of the drug in some countries such as the U.S. With the rise of COVID-19 and decrease in new patients has also contributed to the increased cost and priced of some products and medication. · The price of Opdivo (nivolumab) drug which is a most common therapy treatment for various type of cancer or tumor have been increased to USD 1,172 for a supply of 4 milliliters of injection in 2020 with the rise in demand and increasing patients population in the second quarter of 2020. IMPACT ON DEMAND Global economic development in 2020 has been severely impacted by the COVID-19 pandemic. The COVID-19 has given rise to risks such as a prolonged, significant decline in global demand as well as unfavorable geopolitical and macroeconomic effects. The coronavirus pandemic has provoked many strategical actions among healthcare providers on how to manage cancer patients when faced with the threat of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection. There has been a decrease in demand for nivolumab in some countries like the U.S., whereas many countries have seen an increase in sales with the rise in demand for the treatment and new cancer patients. With the rise in demand for the drug, FDA has provided approval to various drugs related to the immunotherapy nivolumab. For instance- · For the Bristol-Myers Squibb Company, the U.S. revenues of nivolumab decreased to 9% in 2020 due to lower demand caused by declining second-line eligibility across tumor indications and lower demand from COVID-19 (primarily lower new patient starts and patient visits). The U.S. has seen a decrease in sales in the first quarter of 2020. · However, the international revenues for nivolumab were increased up to 7% in 2020 due to higher demand as a result of additional indication launches in some countries with rising cancer patients globally. · In May 2021 -- Bristol-Myers Squibb Company has today announced that the U.S. Food and Drug Administration (FDA) had approved their Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer. · Similarly, FDA has approved Opdivo (nivolumab) for treating different types of cancer in many countries via various market players due to the rise in demand for this drug. IMPACT ON SUPPLY CHAIN The pandemic and COVID-19 have affected every business activity in which the supply chain was affected the most. Because of the pertinacious COVID-19 lockdown, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labor force and the halting of the assembly line. The COVID-19 pandemic has transformed many organizations’ business environments; supply availability has been hampered by a number of issues, including export and travel restrictions by some producing countries, and the lockdown has forced suppliers to (temporarily) shut down. The supply of nivolumab medication has a slight decrease in sales during the first quarter of 2020, partly due to negative factors mentioned above in connection with the COVID-19 pandemic, which particularly didn’t affect the overall yearly revenue. The supply chain and demand were positively affected by the COVID 19. The sales and supply of the drugs have been increased with the rise in demand for the drugs and diagnosis. Many major manufacturing companies have launched their drugs in different countries to fulfill the demand, and the government has provided approval for the sales of the drug nivolumab. For instance- Despite the pandemic, many market player of nivolumab has increased their sales globally. This is due to the ongoing increase in the patient population and rising awareness regarding their health. · The sales of ONO pharmaceuticals have been increased in the year 2020 as compared to 2019, which is 2656.05 USD Million in 2019 and 2809.23 USD million. · Similarly, sales of the drug Opdivo (Nivolumab) from the manufacturing company Bristol Myers Squibb Company have been increased globally (except the U.S.) from USD 2,860 million in 2019 to USD 3,047 million in 2020. This increase in sales in both of the major market players is due to the increase in cancer patients and the use of drugs in all areas of cancer. There is an increase in the sales of this nivolumab with the rise in prevalence of disease and early diagnosis & treatment. STRATEGIC DECISIONS BY MANUFACTURERS To deal with the COVID-19 outbreak challenges and increasing demand for the drugs, many market players are creating new strategies such as new product development, telemedicine, and a different program to support patients and to raise their sales. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. The government has provided drug FDA approvals of nivolumab for the treatment of cancer. For instance, · In May 2020, Bristol Myers Company announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). · There are several ongoing potentially registrational studies that have been conducted by different manufacturing companies for Opdivo for the treatment of different tumor types and disease areas, in combination with various anti-cancer agents · Also, there are various ongoing clinical trials conducting on nivolumab with the combination of various anti-cancer agents and others to treat various types of cancer to decrease the demand for cancer treatment and to provide patients with more advanced drugs. For instance · In Japan, South Korea, and Taiwan, ONO pharmaceuticals are co-developing this drug nivolumab with the Bristol Myers Company CONCLUSION As the pandemic of COVID-19 resulted in several restrictions throughout the borders, still, manufacturers and market players were able to manage their sales and revenue of oncology and drug nivolumab. Various manufacturers allowed their workers to work in a clean and safe environment so as to boost up the production at various manufacturing facilities across several regions of the world, thus, helping them to maintain a continuous supply chain with the increasing demand. Market players have come up with better strategies which have also created a positive impact on the growth of the nivolumab market globally.
Significant COVID-19 Impact on Non-Small Cell Lung Cancer Diagnostics in Healthcare Industry
COVID-19 Impact on Non-Small Cell Lung Cancer Diagnostics in Healthcare Industry The novel coronavirus has profoundly impacted all fields, including healthcare, medical device services, automotive, pharmaceutical and many others. This pandemic has led to shutdowns of mass production and disruptions in the supply chain that have impacted the economies of virtually every nation in the world. The pandemic also affected the non-small cell lung cancer diagnostic industry. The patient's fear of contracting the virus compels patients to stay home instead of undergoing diagnosis and treatment. During the COVID-19 pandemic, countries worldwide witnessed a large number of patients suffering from COVID-19 and post COVID-19 complications such as cardiovascular disease, diabetes and kidney problems. As the COVID-19 cases were rising, the healthcare system had shifted its focus in curbing the disease, thereby delaying diagnosis and treatment of other chronic conditions as cancer. Thus, a negative impact is expected on the non-small cell lung cancer diagnostics market due to the pandemic scenario As a result, the hospitals and clinics were filled up with COVID-19 patients and less preference was given to non-small cell lung cancer patients. Moreover, limited access to clinics, social distancing, the lockdown of the population, which results in a slow-down in patient flow and referrals, has also impacted the market growth. However, with the cases decreasing in number and increase in vaccination against COVID-19 across the globe, the market for non-small cell lung cancer diagnostics market may get a boost due to some relaxation in COVID-19 cases, which will result in increased demand for non-small cell lung cancer diagnosis with patients coming forward to clinics and hospitals for treatment. IMPACT ON DEMAND Various screening, diagnostic and surgical procedures were restricted and at hospitals and cancer treatment centers, which resulted in disruptions in the non-small cell lung cancer diagnostics market. However, even during the pandemic, the lung cancer cases were subsequent, which is expected to increase the demand for non-small cell lung cancer diagnostics market. For instance, · According to World Health Organization (WHO), in 2020, lung cancer accounted for 2,206 771 deaths among both sexes. The lung cancer statistics include both small cell lung cancer and non-small cell lung cancer. About 13% of all lung cancers are small cell lung cancer and 84% are non-small cell lung cancer. This proves an increase in the number of non-small cell lung cancer patients even during the COVID-19 pandemic. Moreover, according to the American Cancer Society, Inc., lung cancer patients are likely to get infected with coronavirus because of the changes in their immune system that control their body's defense systems. For instance, · According to a study published in PubMed, patients with lung cancer are at an increased risk of becoming infected with the virus and experience higher morbidity and mortality than the general population Thus, having cancer such as non-small cell lung cancer may also increase the risk of severe illness from COVID-19 as the cancer therapy treatment reduce the immune system of the body. . This has increased the demand for non-small cell lung cancer diagnostic tools, especially in cancer-dedicated hospitals and surgical centres, where all the patients of non-small cell lung cancer-related problems are treated. Thus, with the increased lung cancer cases, the demand for non-small cell lung cancer diagnostic will increase in the coming years. IMPACT ON SUPPLY CHAIN The supply chain was widely affected by the COVID-19 pandemic as acute restrictions and lockdowns produced many urgent situations in the early days of the pandemic, which needed immediate attention. The supply chain disruption has transformed many organizations' business environments, including the supply chain of non-small cell lung cancer diagnostics market. The supply chain disruption impacted the Asia-Pacific region initially, especially the demand from China due to challenges from restricted movement and quarantine period. For instance, · According to the FDA, 63 manufacturers representing 72 facilities in China that produce essential medical devices face obstacles in manufacturing medical devices and their supply, owing to citing workforce challenges and the necessary quarantine of workers. Moreover, closing borders of various countries is anticipated to diminish the supply chain business environment, as it may hamper export of the medical supplies To minimize supply chain crises, the FDA has been firmly monitoring the supply chain with the assumption that the COVID-19 outbreak may adversely impact the supply chain of medical products, including shortages of critical medical products in the U.S. or potential disruptions in supply chains. Many organizations and countries are looking forward to improving and diversified supply chain models in all aspects to manage such a crucial situation. A diversified supply chain model anticipated minimizing the export of medical products as well as increase end-to-end visibility. For instance, · The Brazilian government published a resolution eliminating import taxes on 141 medical products and hospital equipment · The European Commission made a decision for helping Member States affected by the pandemic to suspend customs duties and VAT on medical devices temporarily · Federal indirect tax body the Goods and Services Tax (GST) Council of India has decided to cut taxes on medical supplies IMPACT ON PRICE The coronavirus disease (COVID-19) pandemic does not significantly impact the global non-small cell lung cancer diagnostics market. But it is estimated that if COVID-19 continues to spread for a prolonged period, then the demand for non-small cell lung cancer diagnostic equipment and devices will highly upsurge for top importer countries. For therapies and the diagnostic United States solicit the huge number of medical devices, followed by China and Japan. For instance, · According to the General Administration of Customs (GAC), China's exports of medical machinery and devices increased 40.5 percent in 2020 compared to the previous year, reaching USD 18.138 billion · According to the World Trade Organisation, the U.S. imports and exports of medical goods increased by 16 %, reaching USD 1,139.00 billion in value Henceforth for diagnosis, dependency of these countries highly increases on other exporters and many countries solely depend on China and the U.S. for the non-small cell lung cancer diagnostic equipment. Consequently, this may lead to a rise in the overall non-small cell lung cancer diagnostic cost. This increase in the price of the non-small cell lung cancer diagnostic may hamper the market growth if it continues to be the same. Additionally, if the lockdown continues to stretch for a long period, then import of non-small cell lung cancer diagnostics market is estimated to get more restricted, which may further lead to a rise in the price of the these devices CONCLUSION It is estimated that the COVID-19 pandemic outbreak has significantly impacted the growth of non-small cell lung cancer diagnostics market as the rising cases of COVID-19 worldwide the healthcare system had shifted its focus in curbing the disease, thereby resulting in the delay of diagnosis and treatment of non-small cell lung cancer. Thus, a negative impact is expected on the non-small cell lung cancer diagnostics market due to the pandemic scenario. However, with the increase in lung cancer patients worldwide, the demand for non-small cell lung cancer diagnostics will increase in the coming years. Moreover, poor lifestyle, smoking, alcohol consumption, lack of physical activity and other factors will contribute to the incidence of chronic disease such as lung cancer, including non-small cell lung, which is anticipated to increase the global non-small cell lung cancer diagnostics market in the coming years.
How COVID-19 Impacted on Oral Care in Healthcare Industry ?
COVID-19 Impact on Oral Care in Healthcare Industry OVERVIEW The COVID-19 pandemic has posed a complex challenge in front of several healthcare companies and proved to be an unprecedented global health threat. This global pandemic has emerged in December 2019 which has been proved as a global pandemic by WHO in March 2020. With the development and introduction of novel coronavirus vaccine, COVID-19 cases have been declined but with the development of mutant coronavirus strain, the overall COVID-19 cases have been surged and are increasing at a rapid rate in India, and the U.K, and other European countries. The most common symptoms associated with this include cough, fever, diarrhea, sore throat, and loss of smell or taste. Patients affected with COVID-19 are at increased risk of developing hepatic manifestations and also experiences damage to liver tissues. COVID-19 has led to the closure and reduced hours of dental practices except for emergency and urgent services, limiting routine care and prevention. Dental care includes aerosol-generating procedures that can increase viral transmission. The pandemic offers an opportunity for the dental profession to shift more toward non-aerosolizing, prevention-centric approaches to care and away from surgical interventions. Direct effects of COVID-19 on oral health include ageusia (an official symptom of COVID-19) and case reports of vesiculobullous lesions and necrotizing periodontal disease. oral care product has a wide portfolio such as breath Fresheners, Mouth Wash, Dental Floss, among other products. The Article here shows the impact of COVID-19 on the oral care market. IMPACT ON PRICE As the mouth is an important place for bacterial colonization due to which it is necessary to use the product for oral hygiene. With the sudden increase in COVID-19 cases, people's concerns for better health had also increased and the link between oral health and COVID-19 infection also expand the health to oral. As India relies on China for 70% of API’s intermediates and bulk ingredients, COVID -19 is expected to hike the price of the ingredient used for an oral care product For instance, · In the year 2021, As Proctor & Gamble announced the third-quarter result in which the net sales increase by 5 %, and also mentioned that they are planning for a price hike in certain product divisions. This step is taken seeking to recover the revenue loss during COVID-19. · According to GlaxoSmithKline plc, the cost of dental consultation and treatment was cited as the concerning factor IMPACT ON DEMAND The coronavirus has affected the various regions of the world and caused the widespread closure of companies and local manufacturing plants. This lockdown and isolation have adversely impacted global economic activity. As studies around the world have shown the improving oral hygiene is expected to increase the chance of generating demand for the product. THE IMPACT OF COVID-19 INFECTION ON ORAL CARE The rising awareness of oral hygiene COVID-19 has increased the demand for a product requires for oral care as the increasing studies for SARS-COV-2 indicated that proper oral hygiene has been reported to decrease the chances of infection which increases the demand for mouth wash, oral povidone solution, novel gargle solution. · However, due to restrictions and aims to reduce COVID-19 transmission, 30% of respondents had visited a dentist less frequently during the pandemic The second cause of increasing demand for oral care products is that approximately 90% of the product used in oral care are over the counter which can be added as the plus point in maintaining the demand for oral care products. The market players in oral care are also focused on the research to bring novel products to interstate commerce. For instance, · Microbac Laboratories, an independent and internationally accredited testing facility worked on behalf of Unilever Research Laboratories, has found that rinsing with mouthwash containing CPC Technology for 30 seconds is effective in reducing the viral load of SARS-CoV-2, the virus that causes Covid-19, by 99.9%. This type of research surge the demand for the oral product · Colgate-Palmolive President mentioned in an interview that they have seen elevated demand for oral care related to viruses, which also boosted the innovative growth related to a premium product This suggests that the increasing prevalence of COVID-19 poses precautionary measures due to which the global population started to take concern for their health hence enhance the demand for oral care. This thus signifies that COVID-19 is accelerating the demand of the oral care market. IMPACT ON SUPPLY The COVID 19 pandemic has affected and badly disrupted the global drug supply chain due to the continuous shut down of manufacturing facilities and restrictions imposed by the government over import and export activities. As per global sources, it was found that the beauty care business is still facing a crisis due to COVID-19. However, oral care market players are in a strong position. The two main leaders Colgate-Palmolive and Johnson and Johnson had seen a lift in sales in Q1 2020. Colgate-Palmoliva has net sales of USD 415 million for Q3 2020, up by 5.5% from the previous year. The surge of demand for oral care increased during COVID-19 however, the global restriction, and state-wise travel restriction has caused challenges for the market player. Moreover, there are many local players also in the oral care market that continued to fulfill the demand in case of any disruption. Oral care is categorized under essential need products which leads to the easy flow of these products. The main challenges during the pandemic is the supply of API’s and Ingredient or excipient used in toothpaste, as China holds the major share in API’s and other chemicals used in oral care and global restriction has somehow affected the supply chain for these products too. This, thus signifies that due to continuous lockdown and several restrictions by government authorities the companies and patients are facing disruption of the supply chain for oral care. However, oral care is categorized under essential care which lowers the effect of supply chain disruption during COVID-19. STRATEGIC DECISIONS OF MANUFACTURERS Collaboration, agreements, strategic initiatives, product launches by market players such as Colgate Palmolive, Hindustan Unilever among others in the oral care market will help them to expand their product portfolio and to provide appropriate products to the consumer. This in turn will lead to increased product sales and hence will put a positive impact on the overall company’s revenue. Oral Care product manufacturing companies are taking so many strategic decisions to cope up with the current scenario of COVID-19. The companies engaged in the manufacturing of toothpaste, mouth wash, gargle solutions among others are adopting several initiatives to accelerate the development of newer products and efficiently supply the product to different end-users. Companies have done collaboration and product launches between 2019 -2020 which supports the sustainable growth in the oral care market For instance, · In September 2020, Colgate Palmolive launched as first-ever vedshakti mouth protect spray, seeking their focus on oral hygiene during COVID-19. · Hindustan Unilever also planned to launch a mouth wash with 99 % in reducing SARS-COV-2 virus and has recently shared the preliminary data. · In April 2020, GlaxoSmithKline Consumer Healthcare Limited (India) merged with Hindustan Unilever Limited (HUL), with HUL responsible for the distribution of GSK’s Consumer Healthcare brands in India, including its leading oral healthcare brand, Sensodyne. · In April 2020, Perrigo Company plc (Ireland) completed the acquisition of the oral care assets of High Ridge Brands (US), which includes Dr. Fresh, LLC. · In December 2019, Colgate-Palmolive Company launched Colgate Optic White Renewal Tooth Paste. · In 2020, Colgate-Palmolive comes up with a recyclable toothpaste tube which will increase the interest of the population and surge the demand for the product leading to growth in revenue of the company Thus, companies operating in the oral care market are adopting several strategies, including collaboration, agreements, acquisition, and market expansion to enhance their business. These strategic decisions by the companies are expected to provide significant opportunities for the market players operating in the oral care market. CONCLUSION As the pandemic of COVID-19 has resulted in several restrictions throughout the borders but still, manufacturers of oral care can manage their stocks. Various manufacturers have allowed their manufacturers to work in a clean and safe environment to boost up the production of oral care categorized under essential need products at various manufacturing facilities across several regions of the world helping them to maintain a continuous supply chain. However, a decrease in doctor’s visit has impacted the market but the majority of products used in oral care are over the counter product which leads to continuous demand for oral care, and by raising the prices the companies are gaining extra profit which is helping them to combat the negative effect on overall revenue.